Mark Devlin Net Worth

Mark Devlin biography

Dr. Mark Devlin serves as Chief Scientific Officer of the Company. As Biology Leader of the Cooperative Research Centre (CRC) for Cancer Therapeutics,Mark was directly involved with the programs that resulted in the initial discovery and development of Amplia’s proprietary Focal Adhesion Kinase (FAK) inhibitor drugs AMP945 and AMP886. He has continued to play an important and active role as a scientific advisor to the company since it was established as a publicly listed company via its acquisition by Innate Therapeutics in May 2018. Mark has held a number of roles involved in drug discovery and development including a decade at the Peter MacCallum Cancer Centre as part of the CRC for Cancer Therapeutics. In addition to the FAK inhibitors that Amplia is developing, Mark and his team were involved in two oncology programs at the CRC that were licensed to Merck Sharp & Dohme and Pfizer in deals with a combined headline value of US$960M including upfront payments of close to US$30M. Most recently, Mark was Chief Executive Officer of CTxONE, a commercial development partner of the CRC for Cancer Therapeutics. Mark holds a PhD in Pharmacology from the University of Melbourne, a Graduate Diploma in Drug Development from the University of New South Wales, and an MBA from Melbourne Business School.